scispace - formally typeset
Search or ask a question

Does fluconazole reduce inflammation? 

Corpus albicans
Azole
Fluconazole
Mycosis
Candida albicans

Answers from top 10 papers

More filters
Papers (10)Insight
Journal Article•DOI
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations
Teemu Kantola, Janne T. Backman, Mikko Niemi, Kari T. Kivistö, Pertti J. Neuvonen 
01 Jun 2000-European Journal of Clinical Pharmacology
104 Citations
Fluconazole has a significant interaction with fluvastatin.
Open access•Journal Article•DOI
Ibuprofen Potentiates the In Vivo Antifungal Activity of Fluconazole against Candida albicans Murine Infection
Sofia Costa-de-Oliveira, Isabel M. Miranda, Ana Silva-Dias, Ana Elisa Bauer de Camargo Silva, Acácio G. Rodrigues, Cidália Pina-Vaz 
01 Jul 2015-Antimicrobial Agents and Chemotherapy
31 Citations
In a murine model of systemic infection, we show that ibuprofen potentiates fluconazole antifungal activity against a fluconazole-resistant strain, drastically reducing the fungal burden and morbidity.
Journal Article•DOI
Fluconazole improves survival in septic shock: a randomized double-blind prospective study.
Sydney Jacobs, David A. Evans, Mohammed Tariq, Nasser Fawzan Al Omar 
01 Jul 2003-Critical Care Medicine
94 Citations
The mechanism of action of fluconazole in reducing multiple organ dysfunction in this group of patients may be attributed to the ability of fluconazole to increase recruitment, improve bactericidal activity of neutrophils, and to contain microorganisms locally.
Open access•Journal Article•DOI
Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance.
Taiga Miyazaki, Taiga Miyazaki, Yoshitsugu Miyazaki, Koichi Izumikawa, Hiroshi Kakeya, Shunichi Miyakoshi, John E. Bennett, Shigeru Kohno 
01 Feb 2006-Antimicrobial Agents and Chemotherapy
48 Citations
Under these conditions, fluconazole was highly effective in reducing the organ burden in both groups.
Journal Article•DOI
Single-dose systemic oral fluconazole for the treatment of vaginal candidiasis
Boris Kaplan, Boris Kaplan, D. Rabinerson, D. Rabinerson, Y. Gibor 
01 Jun 1997-International Journal of Gynecology & Obstetrics
11 Citations
Fluconazole has been found effective by physicians and patients.
Journal Article•DOI
Antifungal treatment strategy in leukemia patients.
Th. Büchner, N Roos 
01 Oct 1992-Annals of Hematology
17 Citations
By its high systemic activity and low toxicity Fluconazole facilitates this approach.
Journal Article•DOI
The use of fluconazole to treat superficial fungal infections in children.
Aditya K. Gupta, Elizabeth A. Cooper, Fernando Montero-Gei 
01 Jul 2003-Dermatologic Clinics
19 Citations
Fluconazole has excellent absorption and good persistence in tissues that suggests it may be useful in superficial fungal infections.
Open access•Journal Article•DOI
Fluconazole at subinhibitory concentrations induces the oxidative- and nitrosative-responsive genes TRR1, GRE2 and YHB1, and enhances the resistance of Candida albicans to phagocytes
David M. Arana, César Nombela, Jesús Pla 
01 Jan 2010-Journal of Antimicrobial Chemotherapy
33 Citations
Subinhibitory concentrations of fluconazole protect against oxidants and killing mediated by phagocytes.
Journal Article•DOI
Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient
Jens Scholz, Martin Schulz, Markus Steinfath, S Höver, Hanswerner Bause 
01 Mar 1995-Journal of Molecular Medicine
14 Citations
Fluconazole is effective for the treatment of fungal infections.
Journal Article•DOI
Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole
Riina Rautemaa, Malcolm Richardson, Michael A. Pfaller, Jaakko Perheentupa, Harri Saxen 
01 Jan 2008-Scandinavian Journal of Infectious Diseases
36 Citations
These results highlight that also topical compounds, in particular miconazole, may influence fluconazole susceptibility.

Related Questions

How can inflammation be reduced in humans?5 answersInflammation can be reduced in humans through various approaches. One approach is adopting a healthy eating pattern that includes whole grains, nuts and seeds, fruits and vegetables, and fish, as these foods are associated with reduced inflammation. Another approach is the use of a composition containing keto acids and/or their salts, such as keto leucine, keto valine, and keto isoleucine, which have been found to reduce inflammation. Additionally, a herbal composition comprising Rehmannia glutinosa, Pueraria lobata, Eriobotrya japonica, Levisticum officinale, and Gynostema pentaphyllum has been shown to alleviate inflammation. Furthermore, the use of antigen-binding molecules or endonucleases that can bind to chromatin, prevent TLR receptor binding, or promote the degradation of proinflammatory histones can also reduce inflammation. Finally, a system and method involving energy wave generation and emission with specific energy densities have been developed to reduce inflammation in animal or human tissue.
How can I reduce inflammation in my liver?10 answers
How can I reduce the inflammation of piles?8 answers
How do you reduce inflammation of an ulcer?9 answers
How many days does it take to reduce inflammation?9 answers
How to decrease inflammation in liver?10 answers

See what other people are reading

What is the risk factor of candidemia?
4 answers
The risk factors for candidemia include cumulative antibiotic exposure for ≥4 days, the need for total parenteral nutrition or peritoneal dialysis, male sex, and delayed sternal closure ≥2 days. Additionally, in patients with severe COVID-19, risk factors for candidemia include the use of central lines, biologic therapy, and paralytic therapy. These risk factors contribute to the development of candidemia in vulnerable populations, such as pediatric patients with congenital heart defects after cardiac surgery and individuals with severe COVID-19. Understanding and monitoring these risk factors are crucial in clinical practice to identify and manage candidemia effectively, especially in high-risk patient populations.Is Candida albicans and Aspergillus niger susceptible against Ulva intestinalis treatments?
5 answers
Candida albicans and Aspergillus niger have been studied in various contexts regarding their susceptibility to different treatments. While Candida albicans has been found to be susceptible to certain antifungal agents like clotrimazole and ketoconazole, Aspergillus niger has shown high efficiency in removing BOD5, NH4, NO3, and EC from wastewater. However, Ulva lactuca extract did not exhibit antimicrobial activity against Candida albicans. On the other hand, Ulva fasciata extract showed promising results in protecting against invasive candidiasis in mice, reducing inflammatory reactions and improving antioxidant defenses. Therefore, based on the available data, Ulva lactuca treatment may not be effective against Candida albicans, while Ulva fasciata extract could potentially offer benefits in combating Candida infections.Which solvent is best to make essential oils solution for antimicrobial activities?
5 answers
The best solvent for making essential oil solutions for antimicrobial activities can vary based on the specific plant material and target microorganisms. Different solvents have been studied for their effectiveness in extracting antimicrobial compounds from plants. Polysorbate 80 (Tween 80) and dimethylsulfoxide (DMSO) have been investigated for their antibacterial activity. Additionally, natural deep eutectic solvents (NADES) have shown promising antimicrobial effects against various bacteria and fungi, including Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans. Furthermore, the study on Kigelia africana highlighted that absolute ethanol, acetone, and ethanol 50% were effective solvents for extracting antimicrobial compounds from different plant parts. Therefore, depending on the specific plant material and target microorganisms, solvents like Tween 80, DMSO, NADES, and ethanol-based solvents can be considered for preparing essential oil solutions with antimicrobial properties.How does the metabolism of glycerol vary between Candida tropicalis strains?
4 answers
The metabolism of glycerol in Candida tropicalis strains can vary significantly based on genetic modifications and environmental conditions. In a study, disruption of the glycerol kinase gene in a xylitol dehydrogenase knockout strain rendered the C. tropicalis strain unable to grow on glycerol. On the other hand, co-expressing NADP+-dependent glycerol dehydrogenase genes in the gk knockout strain led to enhanced xylitol production, showcasing the importance of glycerol metabolism pathways in this yeast. Additionally, other Candida species like C. guilliermondii and C. glabrata exhibit different metabolic responses to glycerol, with C. guilliermondii producing acetate and regenerating NADPH, while C. glabrata accumulates glycerol as an osmolyte under stress conditions. This highlights the diverse strategies employed by Candida species in glycerol metabolism.How can beta-glucan be analyzed by HPLC?
5 answers
Beta-glucan can be analyzed by HPLC (High Performance Liquid Chromatography) to characterize its structure and purity. HPLC analysis of extracted beta-glucan from yeast cells like Saccharomyces cereviseae and Candida albicans shows similarity to standard beta-glucan, with major peaks at 3.22. This method allows for the identification and quantification of beta-glucan components in the samples. Additionally, HPLC can be used to compare beta-glucans from different sources, such as cereals and yeast, to determine their structural similarities and differences. The analysis by HPLC provides valuable insights into the composition and quality of beta-glucan extracts, aiding in research and industrial applications.What are the current global incidence and prevalence rates of candidiasis?
8 answers
The global incidence and prevalence of candidiasis have seen a significant rise over the last two decades, reflecting an urgent health challenge worldwide. Candida bloodstream infections (BSIs) are notably the fourth most common nosocomial BSI, with a reported incidence of 0.21 cases per 1000 admissions in a six-year surveillance study, highlighting the urgent global health challenge posed by candidiasis and its growing antifungal resistance and mortality rates. This increase is part of a broader trend of rising fungal diseases, which affect over a billion people, with more than 1.5 million deaths annually attributed to fungal diseases, including candidiasis. The prevalence of candidiasis, particularly invasive candidiasis, is estimated at approximately 700,000 cases globally each year. This is compounded by the emergence of highly virulent and (multi)drug-resistant strains, such as Candida auris, which have been promoted by the long-term therapeutic and prophylactic use of antifungal drugs in high-risk patients. The COVID-19 pandemic has further complicated the epidemiology of candidiasis, with reports indicating a sharp increase in C. auris candidemia cases. Moreover, the prevalence of Candida albicans, a major causative agent of candidiasis, has been extensively studied, revealing higher positive rates among younger women in Korea, although this represents a fraction of the global burden. The resistance of Candida species to common antifungal treatments, such as azoles, echinocandins, and amphotericin B, varies significantly, with resistance rates to fluconazole among C. parapsilosis isolates estimated at 15.2% globally. These figures underscore the critical need for enhanced surveillance, prompt and accurate diagnosis, and the development of new antifungal treatments to address the growing challenge of candidiasis and its resistance to current therapies.What is the mechanism of antifungal action of chrysin?
4 answers
The antifungal action of chrysin involves multiple mechanisms. Chrysin inhibits the incorporation of radioactive precursors into various macromolecules in yeast cells, affecting DNA, RNA, proteins, polysaccharides, and lipids. Additionally, chrysin alters cell membrane permeability by impacting polyenoic fatty acid biosynthesis, leading to enhanced leakage of UV-absorbing materials from treated cells. Chrysin also exhibits antifungal activity against specific fungi, such as Botrytis cinerea, Mycosphaerella arachidicola, and Physalospora piricola. Furthermore, chrysin's anti-inflammatory effects involve inhibiting xanthine oxidase activity, regulating transporter proteins like URAT1 and GLUT9, and reducing oxidative stress and inflammation through NLRP3 inflammasome signaling pathway inhibition. In bladder cancer cells, chrysin induces apoptosis via the intrinsic pathway, activates endoplasmic reticulum stress, inhibits the STAT3 pathway, and generates reactive oxygen species, suggesting its potential as a therapeutic agent.What is the mechanism of antifungal action of flavonoid - chrysin?
5 answers
The antifungal action of the flavonoid chrysin involves multiple mechanisms. Chrysin inhibits the incorporation of radioactive precursors into various macromolecules in Candida albicans, affecting DNA, RNA, proteins, polysaccharides, and lipids. It also alters cell membrane permeability by impacting polyenoic fatty acid biosynthesis, leading to changes in the yeast cell membrane. Additionally, chrysin exerts anti-inflammatory and antioxidant effects, which may contribute to its antifungal properties. These combined actions make chrysin a potent agent against fungal infections, suggesting its potential as an adjuvant treatment for various fungal-related conditions.How macrophage ROS signaling transcription factor?
5 answers
Macrophage ROS signaling involves various transcription factors. Studies have shown that urokinase plasminogen activator (uPA) induces oxidative stress and cholesterol biosynthesis, leading to the upregulation of paraoxonase 2 (PON2) expression through a signaling cascade involving NADPH oxidase and sterol regulatory binding protein-2 (SREBP-2). Additionally, ultrafine particles have been found to modulate intracellular calcium levels, transcription factor activation, and cytokine production through a ROS-mediated mechanism in alveolar macrophages and human monocytes. Furthermore, the transcription factors STAT6 and Kruppel-like factor 4 (KLF4) have been implicated in implementing M2 polarization in macrophages via the dual catalytic activities of MCP-1-induced protein (MCPIP). These findings collectively highlight the intricate interplay between ROS signaling and transcription factors in regulating macrophage function and polarization.Docking study on Candida albicans
4 answers
A docking study on Candida albicans involves investigating interactions between various compounds and specific targets within the fungus. Studies have explored the molecular interactions of compounds like benzo[g]quinazolines, terpenoids like α-pinene, and polyphenols such as theaflavins and 3-o-malonylglucosidewith key fungal proteins or enzymes. These docking studies aim to understand how these compounds bind to crucial targets like CYP51, thymidylate synthase, δ-14-sterol reductase, and glucosamine-6-phosphate synthase in Candida albicans. The outcomes of these docking studies provide insights into the potential efficacy of these compounds as antifungal agents by disrupting essential fungal processes, inhibiting biofilm formation, and impacting virulence factors, ultimately offering promising avenues for the development of novel antifungal therapeutics.How getting rid of candida biofilms prevents recurrent infections?
5 answers
Getting rid of Candida biofilms is crucial in preventing recurrent infections due to the resilience and treatment evasion capabilities of these biofilms. Candida biofilms are complex structures that protect the fungus from antifungal agents, leading to persistent and recurrent infections with high mortality rates. Biofilms formed by Candida species, especially C. albicans, are inherently resistant to conventional antifungals, making them challenging to eradicate. Studies have shown that antifungal treatments like fluconazole may reduce the growth of planktonic Candida cells but are ineffective against established biofilms, highlighting the need for alternative strategies. Novel approaches such as using biomaterials, probiotics, and dendritic compounds have shown promise in disrupting Candida biofilms and preventing their formation, offering potential solutions to combat recurrent infections.